> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Royalty Pharma Raises 2026 Outlook To $3.5 Billion-Plus In Receipts Despite $150 Million Pelacarsen Charge
- URL: https://www.bullished.co/royalty-pharma-raises-2026-outlook-to-3-5-billion-plus-in-receipts-despite-150-million-e0852b56/
- Published: 2026-11-04T12:51:26.000Z
- Updated: 2026-11-04T12:51:26.000Z
- Description: Third-quarter royalty collections grew 9%, but net income attributable to shareholders fell to $145 million from $284 million.
- Author: Matteo Parrino
- Tags: Earnings, RPRX, Industry: Healthcare

Royalty Pharma, which buys royalties on drugs sold by other companies, raised its 2026 forecast for [Portfolio Receipts](https://www.sec.gov/Archives/edgar/data/0001802768/000180276826000026/rprx-20260930rpplcpressxre.htm?ref=bullished.co) to $3,500 million to $3,550 million, from $3,400 million to $3,500 million, as third-quarter collections grew 9% to $890 million. The company announced the results Wednesday in an [8-K](https://www.sec.gov/Archives/edgar/data/0001802768/000180276826000026/rprx-20261104.htm?ref=bullished.co); profit fell after a $150 million non-cash write-down tied to Novartis's pelacarsen.

## Tremfya and Voranigo lead the quarter

Royalty Receipts, the sales-based payments at the core of the business, rose 9% to $883 million. Tremfya climbed 61% to $80 million and Voranigo 65% to $55 million, with Evrysdi (up 38% to $71 million) and Imdelltra adding to the gain. Evrysdi also benefited from additional royalties acquired in December 2025.

Promacta receipts fell 75% to $9 million on U.S. generic competition, and Imbruvica dropped 24% to $31 million. The new guidance implies Royalty Receipts growth of 10% to 11% for the year and excludes future transactions.

Cost guidance improved too: operating and professional costs are now expected at 5.5% to 6.0% of Portfolio Receipts, from 5.5% to 6.5%. The company says costs are falling from 8.9% in 2025 because the management fee ended when it completed the internalization of its management on May 16, 2025.

## Profit halves on the pelacarsen charge

Net income attributable to Royalty Pharma shareholders was $145 million, against $284 million a year earlier. The quarter carried the $150 million non-cash impairment after Novartis said its Phase 3 pelacarsen trial missed its main goal of reducing cardiovascular events in the overall study population.

Net cash from operating activities slipped 2% to $686 million from $703 million. Adjusted EBITDA rose 8% to $840 million, and Portfolio Cash Flow rose 2% to $673 million.

## Debt paid down, shares bought back

Royalty Pharma repaid a $380 million term loan in July, cutting total debt principal to $8.8 billion from $9.2 billion at June 30\. It ended September with $514 million in cash and repurchased about 1.5 million shares for $87 million in the quarter.

The company, which holds royalties on more than 35 commercial products, said it has announced transactions worth up to $1.9 billion as of November 3, including potential future milestones, with Capital Deployment of $1.6 billion. Third-quarter deals included $100 million each for royalties on Arcutis's Zoryve and Takeda's Mimrylo. CEO Pablo Legorreta said R&D co-funding with large drugmakers, with $1 billion announced this year, is "an important new opportunity for our business."

Royalty Pharma holds its results call at 8:00 a.m. Eastern on Wednesday; Pharvaris's FDA decision date for deucrictibant is April 23, 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Royalty Pharma plc (RPRX)](https://www.sec.gov/Archives/edgar/data/0001802768/000180276826000026/rprx-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit rprx-20260930rpplcpressxre.htm — Royalty Pharma plc 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001802768/000180276826000026/rprx-20260930rpplcpressxre.htm?ref=bullished.co) — SEC EDGAR